Celgene's decade in Europe and how it will reach its $20 billion goal by 2020

When international pharma companies set up in Switzerland, question almost immediately becomes “when are you leaving?” once economic incentives become less enticing. Not so for Celgene (Nasdaq: CELG), who, as of 2015, have spent 10 years with its EMEA headquarters in Boudry, an hour outside Geneva. Tuomo Pätsi, head of Celgene EMEA, was one of three senior members of staff to discuss the company’s anniversary, ethos and goals to 2020 with The Pharma Letter.

The past 10 years

“We have a milestone year this year - we’ve been in Europe for 10 years. It has been a great story, we started from a very humble situation, downtown in Neuchatel, in very simple offices. We had some plans for the future but we could never have imagined that it would turn into what it has.”